Wang, Rutao
Garg, Scot
Gao, Chao
Kawashima, Hideyuki
Ono, Masafumi
Hara, Hironori
van Geuns, Robert-Jan
Morice, Marie-Claude
Davierwala, Piroze M.
Kappetein, Arie Pieter
Holmes, David R.
Wijns, William
Tao, Ling
Onuma, Yoshinobu
Serruys, Patrick W. http://orcid.org/0000-0002-9636-1104
Clinical trials referenced in this document:
Documents that mention this clinical trial
Transcatheter therapies for mitral regurgitation
https://doi.org/10.1016/j.jtcvs.2013.12.002
Impact of repeat revascularization within 5 years on 10-year mortality after percutaneous or surgical revascularization
https://doi.org/10.1007/s00392-023-02211-6
The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery Trial and Registry
https://doi.org/10.1016/j.jtcvs.2015.05.010
Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial
https://doi.org/10.1016/s0140-6736(13)60141-5
Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II
https://doi.org/10.1016/s0140-6736(13)60108-7
Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease
https://doi.org/10.1007/s00392-021-01922-y
Complex coronary anatomy in coronary artery bypass graft surgery: Impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years
https://doi.org/10.1016/j.jtcvs.2010.07.094
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With and Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials
https://doi.org/10.1161/circulationaha.123.065571
Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery
https://doi.org/10.1136/heartjnl-2016-309720
Mortality after multivessel revascularisation involving the proximal left anterior descending artery
https://doi.org/10.1136/heartjnl-2022-320934
Documents that mention this clinical trial
Impact of repeat revascularization within 5 years on 10-year mortality after percutaneous or surgical revascularization
https://doi.org/10.1007/s00392-023-02211-6
Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease
https://doi.org/10.1007/s00392-021-01922-y
Mortality after multivessel revascularisation involving the proximal left anterior descending artery
https://doi.org/10.1136/heartjnl-2022-320934
Funding for this research was provided by:
Science Foundation Research Professorship Award (15/RP/2765)
German Foundation of Heart Research
Article History
Received: 11 May 2021
Accepted: 12 August 2021
First Online: 25 August 2021
Declarations
:
: Dr. Hara reports a grant for studying overseas from Japanese Circulation Society, a grant-in-Aid for JSPS Fellows and a grant from Fukuda Foundation for Medical Technology. Dr. van Geuns reports grants and personal fees from Boston Scientific, grants and personal fees from Abbott Vascular, grants and personal fees from Astra Zeneca, grants and personal fees from Amgen, grants from InfraRedx, outside the submitted work. Dr. Morice reports to work as the CEO of CERC, a CRO which was never involved in the SYNTAX trial at any level, except that submitted the 10-year additional follow-up (for free) to French authorities to get approval. Dr. Morice also reports to work as minor shareholder of electroducer. Dr. Kappetein reports to work as an employee of Medtronic, outside the submitted work. Dr. Wijns reports research grant and honoraria from MicroPort; medical advisor Rede Optimus Research and co-founder Argonauts, an innovation facilitator. Dr. Serruys reports personal fees from Biosensors, Micel Technologies, Sinomedical Sciences Technology, Philips/Volcano, Xeltis, and HeartFlow, outside the submitted work. All the other authors have no disclosures.